Stocks · Healthcare · Medical - Instruments & Supplies
West Pharmaceutical Services, Inc. WST
$364.98 -0.01% Close, Oct 2, 2026 · NYSE · Market cap $25.69B
High qualityStrong trendLow risk
Next earnings report: Oct 22, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Earnings beat analyst estimates in each of the last 8 quarters (average surprise over the last four: +17.2%).
- The stock is in an uptrend: above its 200-day average for 127 trading days, with the 50-day average above the 200-day.
- Revenue over the last four quarters was $3.33B, up 12.4% from a year earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth56Neutral
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Top 43%
- EPS growth (TTM, YoY)Top 43%
- FCF growth (TTM, YoY)Top 40%
- Revenue growth, 3-year CAGRBottom 29%
- Revenue growth accelerationTop 35%
Quality82Strong
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 8%
- Gross marginBottom 25%
- Operating marginTop 13%
- Cash conversion (OCF / net income)Bottom 28%
- Accruals (lower is better)Bottom 26%
- Net debt / EBITDA (lower is better)Top 30%
- Interest coverTop 1%
Value59Neutral
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 24%
- Free-cash-flow yieldTop 31%
- EBITDA / enterprise valueTop 30%
- Sales / enterprise valueBottom 36%
- P/E vs own 5-year history (lower is better)Bottom 25%
Momentum85Strong
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 46%
- 6-month returnTop 22%
- 1-year return vs S&P 500Top 34%
- Distance from 52-week highTop 7%
- Trend checklist (0–4)Top 7%
Revisions78Positive
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 27%
- Consecutive EPS beatsTop 8%
- Share of analysts rating BuyTop 43%
- Upside to consensus price targetBottom 21%
Stability89Strong
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 5%
- Maximum drawdown, 3 yearsTop 28%
- Beta vs S&P 500 (lower is better)Top 29%
- Net debt / EBITDA (lower is better)Top 30%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 11.2% | 12.4% | ↑ |
| EPS growth (YoY) | 17.6% | 17.1% | ↓ |
| Gross margin | 35.3% | 36.8% | ↑ |
| Operating margin | 21.1% | 20.6% | ↓ |
| FCF margin | 11.6% | 13.1% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 12.4% | 11.2% | ↑ | Top 43% |
| EPS growth (TTM, YoY) | 17.1% | 17.6% | ↓ | Top 43% |
| Gross margin | 36.8% | 35.3% | ↑ | Bottom 25% |
| Operating margin | 20.6% | 21.1% | ↓ | Top 13% |
| Net margin | 17.0% | 16.5% | ↑ | — |
| Free-cash-flow margin | 13.1% | 11.6% | ↑ | — |
| Return on invested capital | 15.8% | — | Top 8% | |
| Revenue growth, 3-year CAGR | 2.1% | — | Bottom 29% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 1.17×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -2.4%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 1.0%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +9.9 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -0.15×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 6865.0×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.24%
- Net buyback yield (TTM)
- -0.01%
- Shareholder yield
- 0.23%
- Share count change, 1 year
- -2.1%
- Share count change, 3-year CAGR
- -1.8%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Jul 23, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 8
- Beats in the last 8 reports
- 8 of 8
- Average EPS surprise, last 4
- +17.2%
- Average 2-day reaction, last 8
- +2.3%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $412.83
- Target vs current price
- +13.1%
- Analysts with a rating
- 16
- Share rating Buy or Strong Buy
- 81%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Jul 23, 2026 | +13.9% | -0.8% | -5.8% | -1.6% | — |
| Apr 23, 2026 | +26.8% | +12.9% | +7.6% | +11.3% | +28.4% |
| Feb 12, 2026 | +11.5% | -1.0% | -0.9% | -6.1% | +32.4% |
| Oct 23, 2025 | +16.7% | +10.9% | +2.8% | -6.9% | -9.6% |
| Jul 24, 2025 | +21.9% | +22.8% | +9.6% | +8.4% | +17.5% |
| Apr 24, 2025 | +18.9% | -3.5% | -3.2% | -4.2% | -3.7% |
| Feb 13, 2025 | +6.4% | -38.2% | -36.8% | -30.6% | -33.9% |
| Oct 24, 2024 | +23.3% | +15.4% | +9.3% | +8.8% | +21.4% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Jul 23, 2026 | $2.37 | $2.08 | +13.9% | $872.3M |
| Apr 23, 2026 | $2.13 | $1.68 | +26.8% | $844.9M |
| Feb 12, 2026 | $2.04 | $1.83 | +11.5% | $805.0M |
| Oct 23, 2025 | $1.96 | $1.68 | +16.7% | $804.3M |
| Jul 24, 2025 | $1.84 | $1.51 | +21.9% | $766.2M |
| Apr 24, 2025 | $1.45 | $1.22 | +18.9% | $698.0M |
| Feb 13, 2025 | $1.82 | $1.71 | +6.4% | $748.8M |
| Oct 24, 2024 | $1.85 | $1.50 | +23.3% | $746.9M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 46.7× | 42.4× | 71th | Top 24% |
| P/E (forward) | 40.7× | — | — | — |
| EV / EBITDA | 31.0× | — | — | Top 30% |
| EV / Sales | 7.68× | — | — | Bottom 36% |
| Free-cash-flow yield | 1.70% | — | — | Top 31% |
| Earnings yield | 2.14% | — | — | Top 24% |
P/E over the past five years
Range 26.6× – 60.2× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- +34.5%
- Earnings per share growth (TTM)
- +17.1%
- Change in P/E multiple
- +8.8%
Most of the move came from earnings growth.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✓ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 15
- Days above the 200-day average
- 127
- 50-day average slope (20 days)
- +0.5%
- 200-day average slope (20 days)
- +3.1%
- Distance from 50-day average
- +3.7%
- Distance from 200-day average
- +20.7%
- RSI (14)
- 54.2
- Relative volume
- 0.75×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 25.3%
- Volatility vs own 5-year history
- 14th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.77
- Correlation with S&P 500
- 0.27
- Current drawdown from 1-year high
- -3.1%
- Maximum drawdown, 3 years
- -53.9%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Dec 30, 2021 | Apr 8, 2025 | -59.6% | 820 days | Not yet recovered |
| Jan 8, 2021 | Mar 4, 2021 | -16.3% | 37 days | 29 days (Apr 15, 2021) |
| Sep 8, 2021 | Oct 13, 2021 | -14.1% | 25 days | 54 days (Dec 30, 2021) |
| Oct 12, 2020 | Dec 9, 2020 | -13.4% | 41 days | 19 days (Jan 7, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $25.69B
- P/E (TTM)
- 46.7
- EPS, diluted (TTM)
- $7.82
- Revenue (TTM)
- $3.33B
- Dividend yield
- 0.24%
- 52-week range
- $223.83 – $386.00
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $2.83B | $2.89B | $2.95B | $2.89B | $3.07B |
| Gross profit | $1.17B | $1.14B | $1.13B | $1.00B | $1.10B |
| Operating income | $758.7M | $763.5M | $710.9M | $594.6M | $617.4M |
| Net income | $661.8M | $585.9M | $593.4M | $492.7M | $493.7M |
| EPS (diluted) | $8.67 | $7.73 | $7.88 | $6.69 | $6.80 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $746.9M | $748.5M | $698.2M | $766.2M | $804.3M | $805.0M | $844.9M | $872.3M |
| Net income | $136.0M | $130.1M | $89.8M | $131.8M | $140.0M | $132.1M | $138.8M | $154.0M |
| EPS (diluted) | $1.85 | $1.78 | $1.23 | $1.82 | $1.93 | $1.82 | $1.92 | $2.15 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $584.0M | $724.0M | $776.5M | $653.4M | $754.8M |
| Capital expenditure | -$253.4M | -$284.6M | -$362.0M | -$377.0M | -$285.9M |
| Free cash flow | $330.6M | $439.4M | $414.5M | $276.4M | $468.9M |
| Dividends paid | -$51.1M | -$54.1M | -$57.0M | -$59.1M | -$61.2M |
| Net share buybacks | -$151.9M | -$222.2M | -$451.2M | -$566.6M | -$115.8M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $435.8M
- Total assets
- $4.08B
- Total liabilities
- $1.09B
- Total debt
- $312.1M
- Net debt
- -$123.7M
- Shareholders’ equity
- $2.99B
As of Jun 30, 2026 (filed Jul 23, 2026).
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| Jul 29, 2026 | $0.22 | Aug 5, 2026 |
| Apr 29, 2026 | $0.22 | May 6, 2026 |
| Jan 28, 2026 | $0.22 | Feb 4, 2026 |
| Nov 12, 2025 | $0.22 | Nov 19, 2025 |
| Jul 30, 2025 | $0.21 | Aug 6, 2025 |
| Apr 30, 2025 | $0.21 | May 7, 2025 |
| Feb 7, 2025 | $0.21 | Feb 11, 2025 |
| Nov 13, 2024 | $0.21 | Nov 20, 2024 |
Short interest
- Shares sold short
- 2,378,099
- Days to cover
- 4.51
- Change vs previous report
- +8.3%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Sep 27, 2013
- 2-for-1
- Sep 30, 2004
- 2-for-1
- Jun 2, 1987
- 2-for-1
- May 6, 1982
- 2-for-1